Feb 07, 2019 - U.S. stocks closed lower on Wednesday following disappointing earnings results from videogame companies.
Feb 06, 2019 - LLY earnings call for the period ending December 31, 2018.
Feb 06, 2019 -
Feb 06, 2019 - Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued outlook for earnings and sales. Stock drops in pre-market trading.
Feb 05, 2019 - Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Feb 05, 2019 - Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Feb 05, 2019 - Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Feb 04, 2019 - Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.
Feb 01, 2019 - Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.